Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca Stock: 1 Red Light, 1 Green Light

By Max Macaluso – Feb 3, 2014 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One pro and one con for investors looking at AstraZeneca today.

While AstraZeneca's (AZN 0.55%) stock delivered solid returns in 2013, the company is still in the middle of a multiyear turnaround. With patent expirations just around the corner, and a pipeline that has failed to deliver a new blockbuster therapy in recent years, AstraZeneca's strategy has become the most important factor in its long-term survival in the pharmaceutical industry.

This massive company has several moving parts. But in the video below, Motley Fool analyst Max Macaluso focuses on just one red light and one green light that investors should consider before buying shares today.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

AstraZeneca Plc Stock Quote
AstraZeneca Plc
AZN
$69.55 (0.55%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.